首页|血清PSA、PAP联合检测对前列腺癌诊断价值及雌激素对其影响研究

血清PSA、PAP联合检测对前列腺癌诊断价值及雌激素对其影响研究

扫码查看
研究血清PSA、PAP联合检测对前列腺癌诊断价值及雌激素对其影响.方法 选取2013年6月~2014年6月缙云县人民医院泌尿外科收治的前列腺癌患者60例,给予己烯雌酚3mg,1次/d,口服,同时给予阿司匹林肠溶缓释片100mg,1次/d,口服,连续2个月.同时选取前列腺增生患者60例,正常对照组为同时期体检健康者60例.采用放射免疫分析法,分别观察前列腺增生组、正常对照组、前列腺癌组治疗前、前列腺癌组治疗后血清PSA、PAP水平,以及前列腺癌组患者治疗前后IPSS评分指标.结果 ①前列腺癌组的血清PSA、PAP水平明显高于前列腺增生组和正常对照组,差异有统计学意义(P<0.05);②前列腺增生组与正常对照组比较无明显差异,PSA对前列腺癌的阳性检出率及检测的灵敏性为78.33%,指标特异性达70.00%,而PAP对前列腺癌的阳性检出率及检测的灵敏性为53.33%,指标特异性达93.33%;PSA对前列腺癌检出的阳性率和灵敏性均高于PAP,而特异性却不及PAP,差异有统计学意义(P<0.05);③治疗后,前列腺癌组血清PSA、PAP水平均有所改善,与治疗前比较,血清PSA、PAP水平明显下降,差异有统计学意义(P<0.05);④治疗后,前列腺癌组前列腺症状有所改善,与治疗前比较,IPSS评分明显降低,差异有统计学意义(P<0.05).结论 血清PSA、PAP联合检测能够提高对前列腺癌诊断的灵敏性和特异性,可用于前列腺癌的早期诊断;雌激素能够降低其水平,改善前列腺癌症状,抑制病情进展.
Study on diagnosis of prostate cancer by PAP combined with PSA and the effect of estrogen
Objective To study the serum levels of PSA, PAP joint detection in diagnosis of prostate cancer and the effect of estrogen on it.Methods60 patients with prostate cancer were selected in Jinyun County People's Hospital department of urology patients, giving diethylstilbestrol 3mg, oral once a day, and give Aspirin Enteric-coated Sustained Release Tablets 100mg oral, once daily, for 2 consecutive months.At the same time, we selected 60 cases of patients with benign prostatic hyperplasia, normal control group of 60 healthy subjects were the same period.Using radioimmunoassay, were observed inprostatic hyperplasia group, normal control group, the prostate cancer group before treatment, the prostate cancer group after treatment, serum PSA, PAP levels, as well as the group before and after treatment in patients with prostate cancer IPSS score index.ResultsThe prostate cancer group, serum PSA, PAP levels were significantly higher than that of benign prostatic hyperplasia group and normal control group, the difference was statistically significant (P<0.05);no significant difference was found between the prostatic hyperplasia group and normal control group, PSA in prostate cancer positive detection rate and the detection sensitivity is 78.33% the specificity was 70%, the index of PAP in prostate cancer, and the positive detection rate and the detection sensitivity was 53.33%, specificity index reached 93.33%;PSA for prostate cancer detection positive rate and sensitivity was higher than that of PAP, but the specificity is less than PAP, the difference is statistically significant (P<0.05) after treatment;the prostate cancer group, serum PSA, PAP levels were improved, compared with that before treatment, serum PSA, PAP levels decreased significantly, the difference was statistically significant (P<0.05);and after the treatment, the prostate cancer group of prostate symptoms have improved, compared with before treatment, IPSS score decreased significantly, the difference was statistically significant (P<0.05).ConclusionThe combined detection of serum PSA, PAP in the diagnosis of prostate cancer can improve the sensitivity and specificity, and can be used for early diagnosis of prostate cancer;estrogen can lower their level, improve the symptoms of prostate cancer, inhibit the progress of the disease.

prostate cancerprostate specific antigenprostatic acid phosphataseestrogen

陶红、陈文军

展开 >

缙云县人民医院检验科,浙江丽水321400

缙云县人民医院泌尿外科,浙江丽水321400

前列腺癌 前列腺特异性抗原 前列腺酸性磷酸酶 雌激素

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(5)
  • 3
  • 14